Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §112 only | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AEDER, SEAN E | 1 | 56.9% | +19.6% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.6% | +18.2% |
| CANELLA, KAREN A | 1 | 62.6% | +32.9% |
| SALMON, KATHERINE D | 1 | 42.6% | +38.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17615748 | ANTIBODY CLEAVAGE SITE BINDING MOLECULE | CANELLA, KAREN A | 52d overdue |
| 17939198 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | CHANDRAKUMAR, NIZAL S | 49d overdue |
| 18018807 | PHARMACEUTICAL COMPOSITION COMPRISING CELL EXPRESSING CHIMERIC RECEPTOR | AEDER, SEAN E | 23d overdue |
| 16625877 | KIT FOR EVALUATING GENE MUTATION RELATED TO MYELOPROLIFERATIVE TUMOR | SALMON, KATHERINE D | 14d |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1625 | 1 |
| 1643 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18018807 | PHARMACEUTICAL COMPOSITION COMPRISING CELL EXPRESSING CHIMERIC RECEPTOR | AEDER, SEAN E | 1642 | §103 | Non-Final OA | 23d overdue | Pending | Jan 30, 2023 |
| 17939198 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | CHANDRAKUMAR, NIZAL S | 1625 | §103 | Final Rejection | 49d overdue | Pending | Sep 07, 2022 |
| 17615748 | ANTIBODY CLEAVAGE SITE BINDING MOLECULE | CANELLA, KAREN A | 1643 | §112 | Final Rejection | 52d overdue | Pending | Dec 01, 2021 |
| 16625877 | KIT FOR EVALUATING GENE MUTATION RELATED TO MYELOPROLIFERATIVE TUMOR | SALMON, KATHERINE D | 1682 | §112 | Non-Final OA | 14d | Pending | Dec 23, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial